Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection

Journal of Viral Hepatitis

Volumn 18, Issue 4, 2011, Pages 245-251

  Pedersen, Court ^a,b   Alsio A ^c   Lagging, M ^c   Langeland, N ^d   Farkkila M ^e   Buhl, M Rauning ^f   Morch K ^d   Westin, J ^c   Sangfelt, P ^g   Norkrans, G ^c   Christensen, P Brehm ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF HELSINKI   (Finland)

^f AARHUS UNIVERSITY   (Denmark)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Drug concentration; Hepatitis C; Ribavirin; Treatment

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PLASMA; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79952672318     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01303.x     Document Type: Article

References (28)

1. Hadziyannis SJ, Sette HJ, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346-355.
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
3. Zeuzem S, Berg T, Moeller B et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16: 75-90.
4. Jacobson IM, Brown Jr RS, Freilich B et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients:a randomized trial. Hepatology 2007; 46: 971-981. (Pubitemid 350144761)
5. Shiffman M, Pappas S, Greenbloom S et al. Effect of drug exposure on sustained virological response (SVR) in patients with chronic hepatitis C virus genotype 2 or 3 treated with peginterferon alfa-2a (40KD)(Pegasys®) plus ribavirin (Copegus®) for 16 or 24 weeks. AASLD 2006. Abstract 342. Hepatology 2006; 44 (Suppl. 1): 317A-318A.
6. European Medicines Agency. European Public Assessment Report. Product information Pegintron-H-C-280-II-82. Available at: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Pegintron/emea-combined-h280en.pdf (accessed 2 March 2010).
7. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-1265. (Pubitemid 39656999)
8. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617. (Pubitemid 41007847)
9. von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-527.
10. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134. (Pubitemid 47057730)
11. Lagging M, Langeland N, Pedersen C et al. Randomized comparison of 12 or 24 weeks of peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47(6): 1837-1845. (Pubitemid 351945551)
12. Tarantino G, Craxi A. Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotype 2 and 3:review. Liver Int 2009; 29(Suppl. 1): 31-48.
13. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C genotype 1 patients. Antivir Ther 2008; 13: 607-611. (Pubitemid 352016724)
14. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006; 62(6): 710-714. (Pubitemid 44749548)
15. Rendon AL, Nunez M, Romero M et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39(4): 401-405. (Pubitemid 41003783)
16. Jen FJ, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-565.
17. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-279. (Pubitemid 40165370)
18. Morello J, Rodriguez-Novoa S, Cantillano ALR, Gonzalez-Pardo G, Jiminez I, Soriano V. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monit 2007; 29: 802-806. (Pubitemid 350190858)
19. Jen J, Laughlin M, Chung C et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002; 72: 349-361. (Pubitemid 35178861)
20. Marucco DA, de Requena G, Bonora S et al. The use of through ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother 2008; 61: 919-924. (Pubitemid 351426079)
21. Loustaud-Ratte V, Alain S, Rousseau A et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008; 47(5): 1453-1461. (Pubitemid 351702729)
22. Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009; 50(2): 402-411.
23. Willems B, Hadziyannis SJ, Morgan TR et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? J Hepatol 2007 (Suppl.2): S6 (Abstract 8).
24. Ferenci P, Brunner H, Laferi H et al. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008; 47: 1816-1823. (Pubitemid 351945549)
25. Berg T, Carosi G. Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antivi Ther 2008; 13(Suppl. 1): 17-22.
26. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006; 62(6): 699-709. (Pubitemid 44749547)
27. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19(Suppl. 1): 17-24. (Pubitemid 29220816)
28. Maeda Y, Kiribayashi Y, Moriya T et al. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004; 26(1): 9-15. (Pubitemid 38140904)